Pharmaceutical Research and Clinical Trial Management
MoodMark® has the potential to transform the pharmaceutical R&D landscape.
MoodMark® tests product portfolios to reveal potential antidepressant uses for existing and compound library drugs
MoodMark® helps clinical trial efficiency and predictability by ensuring all subjects are clinically depressed and potential responders, and by adding an objective endpoint in trial protocols.
Drug Discovery
MoodMark® has the potential to reveal new treatments in pharmaceutical companies’ existing libraries and product portfolios
Product Library
→
Test Gs⍺ Effects with MoodMark® LS
→
Identify Library Products That May Impact Depression
Clinical Trials
Antidepressant clinical trials are expensive, high-risk and may fail due to unreliable survey-based subject stratification and large placebo responses. MoodMark® has the potential to reduce clinical trial risk, cost, and timeline, ensures that subjects are clinically depressed, and quantitatively/objectively verifies trial endpoint results.
Subject Selection with
MoodMark® PS
Screen candidates to help characterize trial subjects as:
✓ Clinically depressed
✓ Categorized by severity
✓ Potential responder
+
Results Verification with
MoodMark® TE
Endpoint analyses based on objective biological test results vs. subjective patient surveys
↓
Smaller Trial Size
Helps to reduce trial size by including more potential responders in recruitment
+
Higher Success Rate
Offers potential for improved trial success through improved patient selection and potential to reduce placebo effect